# US 2015/0307880 A1 · Transthyretin allele selective una oligomers for gene silencing

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2015/0307880 A1
- Document ID: US20150307880A1
- Status: Published application
- Kind: A1
- Application number: 14/667,678
- Filed: 2015-03-25
- Published: 2015-10-29
- Earliest claimed: 2014-03-25
- Assignees: Arcturus Therapeutics, Inc.
- Applicants: Arcturus Therapeutics, Inc.
- Inventors: Kiyoshi Tachikawa; Joseph E. Payne; Padmanabh Chivukula
- Web page: https://patentgrep.com/patent/US20150307880A1

## CPC

- C12N 15/113: Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; {Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing (when used in plants C12N15/8218)}
- A61K 9/127: Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K 31/685: one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
- A61K 31/713: Double-stranded nucleic acids or oligonucleotides
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/02: for peripheral neuropathies
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- C12N 2310/14: interfering nucleic acids [NA]
- C12N 2310/32: of the sugar
- C12N 2310/323: modified ring structure
- C12N 2310/344: Position-specific modifications, e.g. on every purine, at the 3'-end
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

This invention provides UNA oligomers for selectively inhibiting V30M TTR expression, which can be used in treating amyloidosis. The UNA oligomers can have a first strand and a second strand, each of the strands being 19-29 monomers in length, the monomers being UNA monomers and nucleic acid monomers. Embodiments include pharmaceutical compositions and methods for treating or preventing TTR-related amyloidosis by administering a UNA oligomer to a subject.

## Claims

### Claim 1

A UNA oligomer for selectively inhibiting V30M TTR expression, the oligomer comprising a first strand and a second strand, each of the strands being 19-29 monomers in length, the monomers comprising UNA monomers and nucleic acid monomers, wherein the oligomer has a duplex structure of from 14 to 29 monomers in length.

### Claim 2 (depends on 1)

The UNA oligomer of claim 1, wherein the second strand has at least one UNA monomer in the duplex region.

### Claim 3 (depends on 2)

The UNA oligomer of claim 2, wherein the at least one UNA monomer in the second strand is at any one of positions 2-8 from the 5′ end.

### Claim 4 (depends on 2)

The UNA oligomer of claim 2, wherein the at least one UNA monomer in the second strand is at any one of positions 9-18 from the 5′ end.

### Claim 5 (depends on 2)

The UNA oligomer of claim 2, wherein the at least one UNA monomer in the second strand is at position 6, 7, 15, 16 or 17 from the 5′ end.

### Claim 6 (depends on 1)

The UNA oligomer of claim 1, wherein the oligomer has an IC50 for reducing V30M TTR expression of less than 20 pM.

### Claim 7 (depends on 1)

The UNA oligomer of claim 1, wherein the oligomer has a selectivity ratio of at least 10, wherein the selectivity ratio is the ratio of the IC50 for reducing wild type TTR expression to the IC50 for reducing V30M TTR expression.

### Claim 8 (depends on 7)

The UNA oligomer of claim 7, wherein the oligomer has a selectivity ratio of at least 20.

### Claim 9 (depends on 7)

The UNA oligomer of claim 7, wherein the oligomer has a selectivity ratio in vitro of at least 50.

### Claim 10 (depends on 1)

The UNA oligomer of claim 1, wherein the oligomer selectively inhibits V30M TTR expression in vivo.

### Claim 11 (depends on 1)

The UNA oligomer of claim 1, wherein the oligomer selectively inhibits V30M TTR expression ex vivo.

### Claim 12 (depends on 1)

The UNA oligomer of claim 1, comprising at least one nucleic acid monomer that is base-modified, sugar-modified, or linkage modified.

### Claim 13 (depends on 1)

The UNA oligomer of claim 1, wherein the oligomer has a blunt end, or has one or more overhangs.

### Claim 14 (depends on 1)

The UNA oligomer of claim 1, wherein the first and second strands are connected and form a duplex region with a loop at one end.

### Claim 15 (depends on 1)

A pharmaceutical composition comprising a UNA oligomer of claim 1 and a pharmaceutically acceptable carrier.

### Claim 16 (depends on 15)

The pharmaceutical composition of claim 15, comprising a lipid formulation.

### Claim 17 (depends on 15)

The pharmaceutical composition of claim 15, comprising one or more lipids selected from cationic lipids, anionic lipids, sterols, pegylated lipids, and any combination of the foregoing.

### Claim 18 (depends on 15)

The pharmaceutical composition of claim 15, wherein the composition is substantially free of liposomes.

### Claim 19 (depends on 15)

The pharmaceutical composition of claim 15, wherein the composition contains liposomes.

### Claim 20 (depends on 1)

A method for treating or preventing TTR-related amyloidosis, comprising administering to a subject in need an effective amount of a UNA oligomer of claim 1.

### Claim 21 (depends on 20)

The method of claim 20, wherein the TTR-related amyloidosis is ATTR.

### Claim 22 (depends on 20)

The method of claim 20, wherein the subject is human.

### Claim 23 (depends on 20)

The method of claim 20, wherein the subject comprises a V30M gene.

### Claim 24 (depends on 20)

The method of claim 20, wherein the method selectively reduces V30M TTR in the subject.

### Claim 25 (depends on 20)

The method of claim 20, wherein the administering is local or systemic.

### Claim 26 (depends on 20)

The method of claim 20, wherein the administering is intravenous, subcutaneous, pulmonary, intramuscular, intraperitoneal, dermal, or oral.

### Claim 27 (depends on 20)

The method of claim 20, wherein the method selectively reduces V30M TTR in the subject by at least 10% greater than control.

### Claim 28 (depends on 20)

The method of claim 20, wherein the effective amount is a dose of from 0.001 to 50.0 mg/kg.

### Claim 29 (depends on 20)

The method of claim 20, wherein TTR mRNA expression is reduced for at least 5 days.

### Claim 30 (depends on 20)

The method of claim 20, wherein the method reduces peripheral neuropathy or autonomic neuropathy in the subject.

### Claim 31 (depends on 20)

The method of claim 20, wherein the administration does not result in an inflammatory response.

### Claim 32 (depends on 1)

A method for inhibiting expression of a TTR gene in a cell, comprising treating the cell with a UNA oligomer of claim 1.

### Claim 33 (depends on 1)

A method for inhibiting expression of a TTR gene in a mammal, comprising administering to the mammal a UNA oligomer of claim 1.
